Loading...
XNYS
ATNM
Market cap46mUSD
Jun 10, Last price  
1.77USD
1D
-8.76%
1Q
53.91%
Jan 2017
102.29%
IPO
-82.30%
Name

Actinium Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
43.30%
Rev. gr., 5y
%
Revenues
0k
-100.00%
0000000000000001,144,0001,030,00081,0000
Net income
-38m
L-21.66%
-18,404-14,800-31,243-22,3311,67410,289-8,361,205-10,773,792-24,687,509-21,025,314-24,321,724-26,601,235-23,653,963-21,726,661-22,037,000-24,584,000-31,930,000-48,818,000-38,243,000
CFO
-33m
L-30.13%
-14,034-15,492-13,964-18,7837,835539-5,212,710-6,292,416-14,348,754-18,543,768-20,789,237-21,553,346-20,571,056-21,461,449-21,617,000-20,866,0008,644,000-47,335,000-33,072,000
Earnings
Aug 04, 2025

Profile

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
IPO date
Mar 26, 2014
Employees
49
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
81
-92.14%
1,030
-9.97%
Cost of revenue
42,121
52,001
35,833
Unusual Expense (Income)
NOPBT
(42,121)
(51,920)
(34,803)
NOPBT Margin
Operating Taxes
(1,087)
Tax Rate
NOPAT
(42,121)
(51,920)
(33,716)
Net income
(38,243)
-21.66%
(48,818)
52.89%
(31,930)
29.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
29,255
14,612
23,158
BB yield
-77.21%
-10.81%
-9.01%
Debt
Debt current
580
1,082
498
Long-term debt
2,566
3,685
4,664
Deferred revenue
35,000
35,000
Other long-term liabilities
35,000
35,000
Net debt
(69,758)
(71,910)
(104,050)
Cash flow
Cash from operating activities
(33,072)
(47,335)
8,644
CAPEX
(11)
(153)
(366)
Cash from investing activities
(11)
(153)
(366)
Cash from financing activities
29,321
14,870
23,109
FCF
(41,321)
(51,841)
(36,025)
Balance
Cash
72,904
76,677
108,910
Long term investments
302
Excess cash
72,904
76,673
109,160
Stockholders' equity
(375,795)
(337,555)
(288,739)
Invested Capital
445,126
411,588
427,801
ROIC
ROCE
EV
Common stock shares outstanding
30,070
26,604
24,142
Price
1.26
-75.20%
5.08
-52.30%
10.65
77.20%
Market cap
37,888
-71.97%
135,149
-47.43%
257,107
107.99%
EV
(31,870)
63,239
153,057
EBITDA
(41,310)
(51,130)
(34,104)
EV/EBITDA
0.77
Interest
1,087
Interest/NOPBT